LNSR 5.47 LENSAR, Inc.
| Range: | 1.8-6.25 | Vol Avg: | 28039 | Last Div: | 0 | Changes: | -0.32 |
| Beta: | 0.64 | Cap: | 0.06B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 02 2020 | Empoloyees: | 130 | ||
| CUSIP: | 52634L108 | CIK: | 0001320350 | ISIN: | US52634L1089 | Country: | US |
| CEO: | Mr. Nicholas T. Curtis | Website: | https://www.lensar.com | ||||
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow